Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.

Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA, USA.
Vaccine (Impact Factor: 3.49). 10/2008; 26(46):5830-4. DOI: 10.1016/j.vaccine.2008.08.032
Source: PubMed

ABSTRACT Pneumococcal polysaccharide vaccine (PPV-23) has been recommended for HIV-infected adults. We investigated factors that could influence PPV-23 effectiveness against all-cause pneumonia in a longitudinal cohort of 23,255 HIV-infected adults receiving care during 1998--2003. Patients who received PPV-23 had a lower rate of pneumonia (IRR = 0.8; 95% CI: 0.8-0.9) than patients who had never been vaccinated, independent of recent CD4 count, HIV viral load, antiretroviral therapy, and history of pneumonia. However, PPV-23 provided no benefit when patients were vaccinated at HIV viral load > 100,000 copies/ml, irrespective of CD4 count at vaccination. Receipt of PPV-23 was associated with lower incidence of all-cause pneumonia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In June, 2012 a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was added to the recommendation for immunocompromised adults who were previously recommended to receive only 23-valent pneumococcal polysaccharide vaccine (PPSV23). PCV13 may be more effective, though it covers fewer disease-causing strains. We examined the incremental cost-effectiveness of adding one dose of PCV13 to the pre-2012 recommendation of PPSV23 for adults with 4 immunocompromising conditions who are at increased risk of pneumococcal disease: HIV/AIDS, hematologic cancer, solid organ transplants, and end stage renal disease. We used a probabilistic model following a single cohort of 302,397 immunocompromised adults. We used vaccination coverage and disease incidence data specific to each immunocompromising condition. Assumptions about PPSV23 and PCV13 vaccine effectiveness were based on two randomized controlled trials and several observational studies conducted among HIV-infected adults. Because no such studies have been conducted among other immunocompromised populations, we made further assumptions about the relative vaccine effectiveness in those groups. Cost-effectiveness ratios were determined for each condition and for all 4 groups in total. Our model indicated that adding one dose of PCV13 to adults in the United States with 4 immunocompromising conditions would cost $16 million (in 2009$) but provide off-setting savings of $21 million per cohort from the societal perspective. These savings come largely from decreased medical costs among adults with end stage renal disease. This dose of PCV13 would prevent 57 cases of invasive pneumococcal disease, 619 cases of hospitalized all-cause pneumonia, avert 93 deaths, and save 1360 quality adjusted life years per cohort. The addition of one dose of PCV13 to the previously recommended PPSV23 doses for adults with selected immunocompromised conditions potentially reduces both disease and costs.
    Vaccine 10/2013; · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Despite a better management of HIV infection, Invasive Pneumococcal Disease (IPD) remains a concern in this population. Epidemiology Incidence of IPD in HIV-infected patients has decreased since the use of antiretroviral therapy but is still several times higher than in HIV-negative population. Some risk factors are known (age, alcohol consumption, smoking, comorbidities and low CD4-cell count), while antiretroviral therapy protects. Vaccination by the 23-valent polysaccharide pneumococcal vaccine was attested to be protective although not fully efficient. Recent studies concerning the use of the pneumococcal conjugate vaccine in HIV-infected children and adults over 50 years with comorbidities show interesting results. The place of this vaccination in the prevention strategy for HIV adults is not yet established. Microbiology and antibiotic resistance Resistance levels to penicillin of pneumococci in France, particularly high ten years ago, is decreasing but is still worrying. Antipneumococcal vaccination of children changed IPD epidemiology in the general population with a global decrease of infections and an increase of episodes due to serotypes not included in the vaccine, less resistant to penicillin. Evolution seems similar in HIV-infected patients. Perspectives Despite a higher incidence, the epidemiology, serotype distribution, antibiotic resistance rates and prognosis of IPD in HIV-infected patients tend to get closer to those of the general population. Vaccination by the recommended polysaccharide pneumococcal vaccine should be more implemented while the use of the conjugate vaccine needs to be clarified.
    Journal des Anti-infectieux. 10/2012; 14(3):127–135.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunocompromised patients are all at risk of invasive pneumococcal disease, of different degrees and timings. However, considerable progress in pneumococcal immunization over the last 30 years should benefit these patients. The 23-valent polysaccharide vaccine has been widely evaluated in these populations, but due to its low immunogenicity, its efficacy is sub-optimal, or even low. The principle of the conjugate vaccine is that, through the protein conjugation with the polysaccharide, the vaccine becomes more immunogenic, T-cell dependent, and thus providing a better early response and a boost effect. The 7-valent conjugate vaccine has been the first one to be evaluated in different immunocompromised populations. We review here the efficacy and safety of the different antipneumococcal vaccines in cancer, transplant and HIV-positive patients and propose a critical appraisal of the current guidelines.
    Expert Review of Vaccines 12/2013; · 4.22 Impact Factor